CDC

- **(5/13)** Updated *Guidance for Fully Vaccinated People*
  - Outside of the healthcare setting, fully vaccinated people no longer need to wear a mask or physically distance in any setting (except where required by federal, state, local, tribal, or territorial laws, rules, and regulations, including local business and workplace guidance) and can refrain from testing and quarantining following a known exposure unless they are residents or employees of a correctional or detention facility or a homeless shelter.

- **(5/12)** *SARS-CoV-2 Variant Classifications and Definitions*
  - A US government interagency group developed a Variant Classification scheme that defines three classes of SARS-CoV-2 variants:
    - Variant of Interest
    - Variant of Concern
    - Variant of High Consequence
  - The B.1.1.7, B.1.351, P.1, B.1.427, and B.1.429 variants circulating in the United States are classified as variants of concern.

- **(5/7)** *Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March – April 2021*
  - By April 21, nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. Seventeen thrombotic events with thrombocytopenia have been reported, including three non-CVST events.

- **(5/7)** *Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021*
  - Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019–20) were 8.2 and 0.05 per 100,000 doses, respectively.
  - Vaccine providers should be aware of anxiety-related events after vaccination and observe all COVID-19 vaccine recipients for any adverse reactions for at least 15 minutes after vaccine administration.

SHEA

- **(4/30)** *US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021* -- JAMA
  - The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S vaccination resumes in the US as well as
investigations into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

- (5/3) The coronavirus vaccine skeptics who changed their minds -- Washington Post
  - “Almost all of them changed their mind because somebody they love told them to, because they saw people around them getting vaccinated.”
  - “[participants] credited Tom Frieden, the former director of the Centers for Disease Control and Prevention under the Obama administration, for helping boost their understanding of the shots.”

WHO

- (5/10) WHO’s COVID-19 Technical Lead, Dr. Maria Van Kerkhove, confirms during a press briefing that the WHO is classifying the variant B1617 found in India as a “variant of concern at the global level.”

- (5/7) WHO gives Emergency Use Listing to Sinopharm Beijing’s COVID-19 vaccine. It is the sixth vaccine to receive WHO validation and is recommended for adults 18 and older with a two-dose schedule, based on the available data.